Led · Seed · Mar 2026

Stratum Biosciences develops SkinSync™, an AI-powered skin biology discovery platform that mines a biobank of over 200,000 real tissue samples to identify novel biomarkers and targets for skin products. The company aims to translate discoveries into composition-of-matter actives and optimized formulations with improved delivery and bioavailability. Stratum has validated its platform through partnerships with global consumer packaged goods leaders and subsidiaries to advance products addressing hyperpigmentation, skin longevity, and eczema. Founded in 2024 by dermatologist Dr. Ross Lane Pearlman and dermatopathologist Dr. Buu Duong, Stratum is a resident company at Johnson & Johnson’s JLABs@NYC and participates in NVIDIA’s Inception program to access advanced computing resources. Following its $2M seed raise, the company is focused on scaling R&D, expanding partnerships, and building a pipeline of IP-backed ingredient and formulation technologies.

Participated · Equity · Oct 2025

Smartlens’ flagship product, miLens, is the world’s first electronics-free soft contact lens capable of continuous intraocular pressure (IOP) measurement. The microfluidic lens pairs with the firm’s AI-powered smartphone imaging platform to capture real-time pressure data and deliver predictive analytics for glaucoma and ocular-hypertension patients. The company is running a multi-site U.S. pivotal trial and has advanced regulatory preparation, manufacturing scale-up, and clinical validation. Market demand appears strong: a Market Scope survey of 166 ophthalmic practitioners showed 96.2 % intend to adopt miLens once available. After securing FDA clearance, Smartlens plans an expedited commercial launch and expects its platform to enable earlier, data-driven interventions that could slow disease progression for the 180 million people affected by glaucoma and ocular hypertension worldwide. The recent $5.2 million bridge financing provides the capital needed to complete the clearance process and prepare for market entry.

Participated · Equity · Aug 2025

Sleep.ai (Consumer Sleep Solutions LLC) offers APIs, SDKs and a consumer app that enable partners to embed clinically validated, AI-driven sleep technology into their products. Its sleep intelligence platform is powered by over 800 million hours of proprietary data, 250+ scientific studies and 90+ publications. The company unifies four capabilities: SleepScore Labs (R&D and validation), the consumer app SleepScore, reimbursed sleep improvement programs such as Dein Schlaf in Germany, and partner-facing APIs/SDKs. Sleep.ai targets partners across digital health, insurance, mental health, women’s health, smart home and hospitality. Led by founder and CEO Colin Lawlor, the company plans to accelerate commercialization and expand partner integrations using the new funding. The product and go-to-market remain focused on scaling AI-powered sleep solutions across health, wellness, insurance, lifestyle and other sectors.

Led · Seed · Sep 2023

Goldilock Secure focuses on safeguarding networks at the physical layer, an approach it believes is essential against today’s sophisticated cyber threats. Its flagship product, the FireBreak™ Physical Connection Controller, enables organizations to sever or re-establish network links remotely and without detectable signals, creating true air-gap-like isolation on demand. This capability targets large enterprises, service providers, critical infrastructure operators, and defense customers that need absolute assurance against advanced persistent threats. Cisco security veteran Gregory Akers has praised the technology for achieving protections unavailable elsewhere. With a newly raised $2 million seed round, the company intends to accelerate product development, enhance FireBreak’s capabilities, and broaden its go-to-market reach. The funds will also support expansion of operational infrastructure and sales efforts as Goldilock Secure positions itself as a leader in physical-layer cybersecurity. No operating metrics such as revenue or user counts were disclosed, but the fresh capital underscores investor confidence in the firm’s unique value proposition.

Participated · Series B · Aug 2023

Seattle-based Membrion, led by CEO and founder Greg Newbloom, provides adaptive water-infrastructure solutions built around its proprietary ceramic desalination membranes. The technology is designed to process the toughest industrial waste streams, allowing manufacturers to reclaim usable water and valuable minerals while meeting evolving environmental regulations and climate-driven pressures. Membrion positions its membranes as a reliability tool for future-proofing production facilities against regulatory shifts and supply-chain risks. With the fresh capital, the company plans to scale operations and accelerate product development. Since inception, Membrion has raised a cumulative $43 million. No revenue or customer counts were disclosed in the article, but the company emphasizes industrial adoption and continued R&D as key growth drivers.